Table 1.
PURE case-cohort participant characteristics
| Subcohort (n=5084) | Death*(n=1985) | Cardiovascular death*(n=561) | Myocardial Infarction*(n=882) | Stroke*( n=663) | Heart failure*(n=264) | Diabetes*(n=1715) | ||
|---|---|---|---|---|---|---|---|---|
| Age, years | 50·79 (9·58) | 58·34 (9·16) | 59·76 (8·24) | 56·82 (9·06) | 57·87 (8·74) | 58·45 (8·95) | 52·56 (9·17) | |
| Sex | ||||||||
| Female | 2149 (42·3%) | 1099 (55·4%) | 340 (60·6%) | 553 (62·7%) | 349 (52·6%) | 140 (53·0%) | 721 (42·0%) | |
| Male | 2935 (57·7%) | 886 (44·6%) | 221 (39·4%) | 329 (37·3%) | 314 (47·4%) | 124 (47·0%) | 994 (58·0%) | |
| Patients with diabetes | 500 (9·8%) | 408 (20·6%) | 146 (26·0%) | 203 (23·0%) | 153 (23·1%) | 68 (25·8%) | .. | |
| Systolic blood pressure | 134·68 (23·46) | 146·20 (26·42) | 151·97 (26·06) | 145·60 (24·73) | 152·33 (27·88) | 152·21 (26·75) | 140·58 (22·86) | |
| Smoking | 2010 (39·5%) | 1152 (58·0%) | 333 (59·4%) | 508 (57·6%) | 328 (49·5%) | 140 (53·0%) | 627 (36·6%) | |
| Body-mass index | 27·25 (5·45) | 27·32 (6·31) | 27·93 (6·43) | 28·13 (5·95) | 27·66 (5·65) | 29·16 (6·55) | 30·79 (5·46) | |
| Ethnicity | ||||||||
| African | 396 (7·8%) | 289 (14·6%) | 59 (10·5%) | 13 (1·5%) | 31 (4·7%) | 24 (9·1%) | 40 (2·3%) | |
| Arab | 129 (2·5%) | 27 (1·4%) | 6 (1·1) | 17 (1·9%) | 14 (2·1%) | 8 (3·0%) | 81 (4·7%) | |
| East Asian | 97 (1·9%) | 60 (3·0%) | 25 (4·5%) | 30 (3·4%) | 36 (5·4%) | 3 (1·1%) | 35 (2·0%) | |
| European | 1060 (20·8%) | 372 (18·7%) | 65 (11·6%) | 226 (25·6%) | 192 (29·0) | 77 (29·2%) | 322 (18·8%) | |
| Latin American | 2291 (45·1%) | 1043 (52·5%) | 320 (57·0%) | 378 (42·9%) | 270 (40·7%) | 137 (51·9%) | 696 (40·6%) | |
| Persian | 746 (14·7%) | 103 (5·2%) | 42 (7·5%) | 114 (12·9%) | 54 (8·1%) | 12 (4·5%) | 469 (27·3%) | |
| South Asian | 365 (7·2%) | 91 (4·6%) | 44 (7·8%) | 104 (11·8%) | 66 (10·0%) | 3 (1·1%) | 72 (4·2%) | |
| Non-HDL cholesterol, mmol/L | 3·91 (1·04) | 3·92 (1·15) | 4·07 (1·16) | 4·23 (1·09) | 4·14 (1·13) | 4·06 (1·20) | 4·22 (1·04) | |
| LDL, mmol/L | 3·14 (0·88) | 3·05 (0·95) | 3·11 (0·93) | 3·23 (0·95) | 3·19 (0·96) | 3·11 (1·00) | 3·21 (0·86) | |
| Triglyceride, mmol/L | 1·63 (1·29) | 1·81 (1·51) | 1·96 (1·39) | 2·00 (1·39) | 1·88 (1·77) | 1·80 (1·29) | 2·12 (1·51) | |
| History of hypertension | 2184 (43·0%) | 1265 (63·7%) | 425 (75·8%) | 553 (62·7%) | 464 (70·0) | 205 (77·7%) | 973 (56·7%) | |
| History of coronary heart disease | 188 (3·7%) | 192 (9·7%) | 104 (18·5%) | 137 (15·5%) | 62 (9·4%) | 44 (16·7%) | 85 (5·0%) | |
| On blood pressure-lowering medication | 1144 (22·5%) | 822 (41·4%) | 308 (54·9%) | 372 (42·2%) | 293 (44·2%) | 152 (57·6%) | 597 (34·8%) | |
| On cholesterol-lowering medication† | 345 (6·8%) | 219 (11·0%) | 71 (12·7%) | 140 (15·9%) | 106 (16·0%) | 46 (17·4%) | 231 (13·5%) | |
*
Includes cases that are within and outside of the subcohort; participants may have multiple incident events.
†
Statin or other cholesterol-lowering medication.